Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells
NY Villa, S Bais, WM Chan, AM Meacham, E Wise… - Cytotherapy, 2016 - Elsevier
Background Relapsing disease is a major challenge after hematopoietic cell transplantation
for hematological malignancies. Myxoma virus (MYXV) is an oncolytic virus that can target
and eliminate contaminating cancer cells from auto-transplant grafts. The aims of this study
were to examine the impact of MYXV on normal hematopoietic stem and progenitor cells
and define the optimal treatment conditions for ex vivo virotherapy. Methods Bone marrow
(BM) and mobilized peripheral blood stem cells (mPBSCs) from patients with hematologic …
for hematological malignancies. Myxoma virus (MYXV) is an oncolytic virus that can target
and eliminate contaminating cancer cells from auto-transplant grafts. The aims of this study
were to examine the impact of MYXV on normal hematopoietic stem and progenitor cells
and define the optimal treatment conditions for ex vivo virotherapy. Methods Bone marrow
(BM) and mobilized peripheral blood stem cells (mPBSCs) from patients with hematologic …